The research focused on a trispecific antibody known as SAR441236, developed by ModeX Therapeutics Inc., a subsidiary of OPKO Health.

Elysium Therapeutics has made significant strides in enhancing opioid safety through the successful Phase 1 clinical trial of its O2P™ hydrocodone prodrug.

Grace Science, LLC has initiated a clinical trial for GS-100, a gene therapy developed to treat NGLY1 Deficiency, with the first patient receiving the treatment.

Ankyra Therapeutics has reached a pivotal moment with the commencement of patient dosing in a Phase 1 clinical trial for their drug candidate, ANK-101.

In a recent clinical trial, the use of N-803 in combination with natural killer (NK) cells demonstrated promising results in potentially lowering the viral load for individuals with HIV.

Pfizer has achieved a clinical milestone for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223), triggering a $7 million payment to LAVA.

The study, designated M24-122, is assessing the efficacy and safety of ABBV-303 both as a standalone treatment and in tandem with AbbVie's immunotherapy budigalimab (ABBV-181).

CASI Pharmaceuticals have unveiled promising preliminary data for BI-1206 combined with rituximab in Chinese patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL).

ECUR-506, a gene editing therapy developed through a partnership with Precision BioSciences, Inc.

Biopharmaceutical firm OnCusp Therapeutics has initiated a Phase 1 clinical trial for CUSP06, an innovative CDH6-directed antibody-drug conjugate (ADC).

Innate Pharma SA has initiated a Phase 1/2 clinical trial to evaluate the safety and tolerability of IPH6501.

Kura Oncology, Inc. has commenced the first patient dosing with KO-2806, a farnesyl transferase inhibitor (FTI), combined with tyrosine kinase inhibitor (TKI) cabozantinib.